Vernalis gets buy rating from Jefferies

Jefferies & Co., Inc. analyst Robin Campbell rated Vernalis at buy despite the company's missing Apokyn guidance in the first half of 2006. Pipeline events over the next 6 to 12 months and a potential Frova approval could keep the share price up. Campbell lowered the price target to 120p, from 125p. Shares of the Cambridge, England-based pharmaceutical company were down 0.25p, or 0.38%, at 65.75p. (London: VER)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.